Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD -- The Pro Argument
THE EFFECTS OF INHALED CORTICOSTEROID MONOTHERAPY Airway inflammation is a prominent feature of chronic obstructive pulmonary disease (COPD), even among ex-smokers (1), and its intensity is directly related to the severity of the underlying COPD (2). The inflammatory burden increases during pe...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2004-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2004/178072 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | THE EFFECTS OF INHALED CORTICOSTEROID MONOTHERAPY Airway inflammation is a prominent feature of chronic obstructive pulmonary disease (COPD), even among ex-smokers (1), and its intensity is directly related to the severity of the underlying COPD (2). The inflammatory burden increases during periods of clinical exacerbation (3-5). Predictably, use of systemic corticosteroids during these episodes accelerates clinical recovery and improves health outcomes over several months of follow-up (6). Unfortunately, long term use of systemic corticosteroids is generally precluded by their toxic side effects. Inhaled corticosteroids, on the other hand, share much of the anti-inflammatory properties of the systemic formulations without the side effects (7). However, their effectiveness has been questioned and is a matter of heated debate among members of the scientific community (8,9). |
|---|---|
| ISSN: | 1198-2241 |